A MULTI-CENTER, RANDOMIZED, BLINDED STUDY COMPARING THE EFFECT OF CRx-150 PLUS DMARD THERAPY TO THAT OF PLACEBO PLUS DMARD THERAPY ON SERUM C-REACTIVE PROTEIN (CRP) AND CYTOKINES IN SUBJECTS WITH RHEUMATOID ARTHRITIS

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Jun 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amoxapine/dipyridamole (Primary)
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms CRx150RA
Sponsors Zalicus

Most Recent Events

08 Jun 2011 New source identified and integrated (European Clinical Trials Database)
29 Jun 2007 According to CombinatoRx media release, product candidate CRx-150 [amoxapine/dipyridamole] shows activity on DAS28 and Pain, but Not CRP, failing to meet target product profile.
29 Jun 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight